Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD

Related

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in AMD

  John T. Thompson, MD

  Andrew A. Moshfeghi, MD, MBA, FASRS

  Manjot K Gill, MD, FASRS

  Christina Y Weng, MD, MBA, FASRS

  Ferhina S Ali, MD, MPH

  Ian Pearce, MB ChB BSc FRCOPHTH

  Annual Meeting Talks

  2024

• 

  Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema

  John W. Kitchens, MD

  Annual Meeting Talks

  2022

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024